HYBRID EVENT: You can participate in person at Rome, Itlay or Virtually from your home or work.

11th Edition of International Conference on

Neurology and Neurological Disorders

June 05-07, 2025 | Rome, Italy

Cholinesterase Inhibitor

Cholinesterase Inhibitor

Cholinesterase inhibitors are drugs used to treat certain medical conditions, such as Alzheimer’s and Parkinson’s diseases. They work by reducing the activity of cholinesterase, an enzyme responsible for breaking down acetylcholine (ACh), a neurotransmitter involved in sending messages from one nerve cell to another. By inhibiting the enzyme, cholinesterase inhibitors increase the amount of ACh available to be used by neurons, thus resulting in improved nerve conduction and improved cognitive function. Cholinesterase inhibitors come in two forms : reversible and irreversible. Reversible inhibitors temporarily bind to the enzyme for a short period of time, causing it to become temporarily unable to break down ACh. Irreversible inhibitors are more potent and are covalently, or permanently, bound to the enzyme, causing it to become permanently unable to break down ACh. The most commonly prescribed cholinesterase inhibitors are donepezil, rivastigmine and galantamine, which are reversible inhibitors. These drugs are primarily used to treat cognitive impairment associated with Alzheimer’s disease. They are thought to improve cognition by increasing synaptic concentrations of ACh, thus restoring the balance of neurotransmitters in the brain. In addition to treating Alzheimer’s disease, the cholinesterase inhibitors donepezil, rivastigmine and galantamine have also been used to treat other neurological conditions, such as Parkinson’s disease. These drugs are thought to work by increasing the availability of ACh, thus promoting better nerve conduction in the basal ganglia, the part of the brain that controls movement. Finally, the cholinesterase inhibitors donepezil, rivastigmine and galantamine have also been used to treat cognitive impairment in people with dementia. In many of these cases, the drugs have been found to improve memory, language and visual-spatial skills. Overall, cholinesterase inhibitors are a widely used class of drugs that work by increasing the availability of ACh, thereby improving cognitive function. Their effectiveness has been researched extensively and they are commonly used to treat Alzheimer’s disease, Parkinson’s disease and other forms of dementia.

Committee Members
Speaker at Neurology and Neurological Disorders 2025 - Ken Ware

Ken Ware

NeuroPhysics Therapy Institute, Australia
Speaker at Neurology and Neurological Disorders 2025 - Robert B Slocum

Robert B Slocum

University of Kentucky HealthCare, United States
Speaker at Neurology and Neurological Disorders 2025 - Luiz Moutinho

Luiz Moutinho

University of Suffolk, United Kingdom
Neurology 2025 Speakers
Speaker at Neurology and Neurological Disorders 2025 - David Lominadze

David Lominadze

University of South Florida, United States
Speaker at Neurology and Neurological Disorders 2025 - Milton C R Medeiros

Milton C R Medeiros

Irmandade Santa Casa de Arapongas PR, Brazil
Speaker at Neurology and Neurological Disorders 2025 - Sang Hie Lee

Sang Hie Lee

University of South Florida, United States
Speaker at Neurology and Neurological Disorders 2025 - Sergei M Danilov

Sergei M Danilov

University of Illinois, United States
Tags

Submit your abstract Today

Watsapp